

April 22, 2022

Dear Shareholders,

Barring major news, we don't intend to have lengthy updates quarterly. Please feel free to reach out with any specific questions.

Our Sales Efforts

We have hired five salespeople since October, but only three remain employed with the company at present. It is still not clear whether the gross margin dollars produced by new sales per salesperson justify the expense. You will see the sales force investment reflected in higher operating expenses in this quarter's financials. For the quarter, sales were slightly down y.o.y., possibly reflecting an ongoing normalization from the COVID boom in demand for the PharmChek product. We hope to come to a quantitative result about the ROIC from our salesforce investment over the next 6-9 months.

While we are continuing to onboard many smaller new customers, we believe we have come to an agreement with a material new distribution customer (>10% of sales) resulting from our salesforce's efforts. This relationship has not yet yielded an order, and we have no certainty if or when it will.

We are eager to test the market response to our new offering of a [fentanyl panel](#), an additional Add-On, available as of April 1st to test for this increasingly prevalent synthetic opioid.

The Market for our Stock

We were proud to achieve a partial up-listing to "Pink" status on the OTC Markets this quarter, from "Limited," recognizing our increased level of financial disclosure over the last seven months.

Our 10b-5 buyback continues in the open market. So far, we have bought in a small amount of shares outstanding (<1%) to date with the free cash flow generated from ongoing operations.

Our Annual Meeting will be held in Fort Worth, Texas, on August 31, with details to follow. We hope to see you there.

Thank you again for the trust you've put in us.

Tice Brown



Chairman of the Board

****Please read the Disclaimer on the Following Page.****

DISCLAIMER



This letter contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933 (“Forward-looking Statements”), which are subject to the “safe harbor” created by these Sections. Forward-looking statements are statements about future financial results, future products or services and www.pharmchem.com other events that have not yet occurred. These forward-looking statements contain words such as, but not limited to, “expect”, “anticipate”, “estimate”, “believe”, “will”, “may” or “might”. Investors should be aware that actual results may differ materially from our expressed expectations because of risks and uncertainties about the future. We will not necessarily update the information in this letter if any forward-looking statement later turns out to be inaccurate.

To supplement our unaudited condensed consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including Return on Invested Capital (ROIC), free cash flow (FCF), steady-state free cash flow, and steady-state free cash flow per share that exclude certain amounts, one-time expenses from corporate actions and new sales force employee compensation costs. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

We believe that presenting Return on Invested Capital, free cash flow, steady-state free cash flow, and steady-state free cash flow per share, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

PHARMCHEM, INC.

BALANCE SHEETS

March 31, 2022 and December 31, 2021

	March 31, 2022 (unaudited)	December 31, 2021 (audited)
Assets		
Current assets:		
Cash and cash equivalents	\$ 2,260,698	\$ 2,217,270
Accounts receivable, net of allowance for doubtful accounts of \$15,000 in 2021 and 2020	694,816	676,883
Income tax receivable	241,200	241,200
Inventories	239,122	68,009
Prepaid expenses and other current assets	54,435	20,124
Total current assets	3,490,271	3,223,486
 Office equipment and leasehold improvements, net	585	627
Deferred tax asset, net	166,861	166,861
 Total assets	<u>\$ 3,657,717</u>	<u>\$ 3,390,974</u>
 Liabilities and Stockholders' Equity		
Current Liabilities:		
Accounts payable	\$ 228,193	\$ 188,941
Accrued expenses and other liabilities	139,355	265,745
Deferred revenue	99,112	87,772
Total liabilities	466,660	542,458
 Commitments and contingencies		
 Stockholders' equity:		
Common stock, \$0.001 par value, 25,000,000 shares authorized, 5,103,273 issued and outstanding	5,103	5,103
Additional paid-in capital	13,819,663	13,819,663
Accumulated deficit	(10,633,709)	(10,976,250)
Total stockholders' equity	3,191,057	2,848,516
 Total liabilities and stockholders' equity	<u>\$ 3,657,717</u>	<u>\$ 3,390,974</u>

PHARMCHEM, INC.

STATEMENTS OF INCOME

Three Months Ended March 31, 2022 and 2021
(unaudited)

	Three Months Ended March 31, 2022	Three Months Ended March 31, 2021
Sales, net	\$ 1,540,328	\$ 1,641,470
Cost of sales	562,142	600,230
Gross profit	978,186	1,041,240
Operating expenses:		
Sales and marketing	278,475	104,766
General and administrative	357,675	399,402
Total operating expenses	636,150	504,168
Income from operations	342,036	537,072
Other income (expense):		
Dividend and interest income	178	702
Other income (expense)	327	-
Total other income	505	702
Income before provision for income taxes	342,541	537,774
Provision for income taxes	-	118,980
Net income	\$ 342,541	\$ 418,794
Earnings per Share	\$0.067	\$0.072
Diluted Earnings per Share	\$0.064	\$0.060
Common shares outstanding	5,103,273	5,852,593
Diluted common shares outstanding	5,343,273	6,992,593

PHARMCHEM, INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

Three Months Ended March 31, 2022
(unaudited)

	<u>Common Stock</u>	<u>Additional Paid in Capital</u>	<u>Accumulated Deficit</u>	<u>Total</u>
Balance at December 31, 2020	\$5,853	\$19,629,983	\$(12,126,019)	\$7,509,817
Net Income			1,852,080	1,852,080
Dividends Paid			(702,311)	(702,311)
Repurchase of Options		(2,282,619)		(2,282,619)
Repurchase of Common Stock	<u>(750)</u>	<u>(3,527,701)</u>		<u>(3,528,451)</u>
Balance at December 31, 2021	\$5,103	\$13,819,663	\$(10,976,250)	\$2,848,516
Net Income			<u>342,541</u>	<u>342,541</u>
Balance at March 31, 2022	<u><u>\$5,103</u></u>	<u><u>\$13,819,663</u></u>	<u><u>\$(10,633,709)</u></u>	<u><u>\$3,191,057</u></u>

PHARMCHEM, INC.

STATEMENTS OF CASH FLOWS

Three Months Ended March 31, 2022 and 2021
(unaudited)

	<u>March 31, 2022</u>	<u>March 31, 2021</u>
Operating Activities		
Net income	\$ 342,541	\$ 418,794
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	42	42
Provision for doubtful accounts	-	-
Net realized (gain) on investments in marketable securities	-	-
Net changes in operating assets and liabilities:		
Accounts receivable	(17,769)	(162,281)
Bad debt recoveries	(164)	-
Inventories	(171,113)	(46,777)
Prepaid expenses and other current assets	(34,311)	13,977
Accounts payable	36,808	103,774
Accrued expenses and other liabilities	(123,946)	(317,413)
Deferred revenue	11,340	7,260
Total Adjustments	<u>(299,113)</u>	<u>(401,418)</u>
Net cash provided by operating activities	43,428	17,376
Investing Activities		
NetSuite Capitalization	-	(23,990)
Net cash provided by (used in) investing activities	<u>-</u>	<u>(23,990)</u>
Financing Activities		
Dividends paid	-	-
Net cash used in financing activities	<u>-</u>	<u>-</u>
Net (decrease)/increase in cash and equivalents	43,428	(6,614)
Cash and equivalents at beginning of year	<u>2,217,270</u>	<u>7,854,649</u>
Cash and equivalents at end of quarter	<u><u>\$ 2,260,698</u></u>	<u><u>\$ 7,848,035</u></u>
Supplemental Disclosure of Cash Flow Information		
Cash paid during the year for federal and state income taxes	<u><u>\$ -</u></u>	<u><u>\$ -</u></u>

Alternative Reporting Standard: Pink® Basic Disclosure Guidelines

Federal securities laws, such as Rules 10b-5 and 15c2-11 of the Securities Exchange Act of 1934 (“Exchange Act”) as well as Rule 144 of the Securities Act of 1933 (“Securities Act”), and state Blue Sky laws, require issuers to provide *current information* to the public markets. With a view to facilitating compliance with these laws, OTC Markets Group has created these Pink Basic Disclosure Guidelines (“Guidelines”).¹ These Guidelines set forth the disclosure obligations that make up the “Alternative Reporting Standard” for Pink companies. These Guidelines have been designed to encompass the “Catch All” information required in Rule 15c2-11,² however they have not been reviewed by the U.S. Securities and Exchange Commission or any state securities regulator. We use information provided by companies under these Guidelines to designate the appropriate tier in the Pink Market: Current Information or Limited Information.³

These Guidelines may be amended from time to time, in the sole and absolute discretion of OTC Markets Group, with or without notice. The information provided by companies under these Guidelines is subject to our [Privacy Policy](#).

Pink Current Information Tier

Companies that make the information described below publicly available on a timely basis (90 days after fiscal year end for Annual Reports; 45 days after each fiscal quarter end for Quarterly Reports) may qualify for the Current Information Tier.

Qualification Process:

1. Subscribe to the OTC Disclosure & News Service by submitting an [OTCIQ Order Form](#) (available on www.otciq.com).
2. Upload the following documents through OTCIQ:
 - **Quarterly Reports** for Current Fiscal Year– must include Disclosure Statement and Financial Reports listed below
 - **Annual Report** for Most Recently Completed Fiscal Year– must include Disclosure Statement and Financial Reports listed below
 - **Annual Report** for Prior Completed Fiscal Year – must include Financial Reports listed below
 - **Disclosure Statements:** Disclosure information pursuant to these Guidelines for the applicable period. (see the fillable form starting on Page 4).
 - **Financial Statements:** Financial reports must be prepared according to U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited. Required financial statements include:
 - Balance Sheet
 - Statement of Income
 - Statement of Cash Flows

¹ This is not legal advice, and OTC Markets Group makes no assurance that compliance with our disclosure requirements will satisfy any legal requirements.

² Publication of information pursuant to these Guidelines does not guarantee or ensure that the Company will be designated as having “current information” or eligible for public quotations pursuant to Rule 15c2-11 or any other applicable regulation.

³ OTC Markets Group may require companies with securities designated as Caveat Emptor to make additional disclosures in order to qualify for the Pink Current Information tier.

- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
 - Notes to Financial Statements
 - Audit Letter, if audited
3. If financial statements are not audited by a PCAOB registered firm, provide the following:
 - **Attorney Letter Agreement:** Submit a signed Attorney Letter Agreement according to the [instructions](http://www.otcmarkets.com) on www.otcmarkets.com.
 - **Attorney Letter:** After following the appropriate procedures with a qualified attorney, upload an "Attorney Letter With Respect to Current Information" in accordance with the [Attorney Letter Guidelines](#) through OTCIQ. Attorney Letters must reference all required reports as set forth in Section 2 above.
 4. **Verified Profile:** Verify the Company Profile through OTCIQ. Profile information includes, but is not limited to, a complete list of officers, directors and service providers, outstanding shares, a business description and contact information.
 5. Allow OTC Markets Group to process the posted documents (typically three to five business days) and provide any comments.
 6. Companies will only be evaluated for Current Information once all required documentation has been submitted. A new Attorney Letter is required upon amendment of any referenced report.
 7. To qualify for Current Information on an ongoing basis, companies must:
 - Upload reports through OTCIQ on the following schedule:
 - Quarterly Report within **45 days** of the quarter end
 - Annual Report within **90 days** of the fiscal year end
 - Attorney Letter within **120 days** of the fiscal year end.
 - Maintain a Verified Profile. At least once every six months, review and verify the Company's profile information through OTCIQ.

Pink Limited Information Tier

Companies that make the information described below publicly available through OTCIQ may qualify for the Limited Information Tier.

8. **Annual Financial Statements:** Companies must upload the below financial statements for a completed Fiscal Year within the past 16 months. Financial reports must be prepared according to U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.
 - Balance Sheet
 - Statement of Income
 - Statement of Cash Flows
 - Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
 - Notes to Financial Statements
 - Audit Letter, if audited
9. **Verified Profile:** The Company must verify the Company Profile through OTCIQ, including, but not limited to, a complete list of officers, directors and service providers; outstanding shares; a business description and contact information.

10. To Qualify for Limited Information on an ongoing basis, companies must:

- Upload reports through OTCIQ on the following schedule:
 - **Annual Report** (including the required financial statements outlined in Item 8) within 120 days of the fiscal year end
- Maintain a Verified Profile. At least once every six months, review and verify their the Company's profile information through OTCIQ.

Current Reporting of Material Corporate Events

Companies are expected to release quickly to the public any news or information regarding corporate events that may be material to the issuer and its securities (including adverse information). Persons with knowledge of such events would be considered to be in possession of material nonpublic information and may not buy or sell the issuer's securities until or unless such information is made public. If not included in the issuer's previous public disclosure documents or if any of the following events occur after the publication of such disclosure documents, the issuer shall publicly disclose such events by disseminating a news release within 4 business days following their occurrence and posting such news release through an Integrated Newswire or OTCIQ.⁴

Material corporate events include:

- Entry into or termination of a material definitive agreement
- Completion of an acquisition or disposition of assets, including but not limited to merger transactions
- Creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of an issuer
- Triggering events that accelerate or increase a direct financial obligation or an obligation under an off-balance sheet arrangement
- Costs associated with exit or disposal activities
- Material impairments
- Sales of equity securities
- Material modification to rights of security holders
- Changes in issuer's certifying accountant
- Non-reliance on previously issued financial statements or a related audit report or completed interim review
- Changes in control of issuer
- Departure of directors or principal officers; election of directors; appointment of principal officers
- Amendments to articles of incorporation or bylaws; change in fiscal year
- Amendments to the issuer's code of ethics, or waiver of a provision of the code of ethics
- Any changes to litigation the issuer may be involved in, or any new litigation surrounding the issuer
- Officer, director, or insider transactions in the issuer's securities
- Disclosure regarding stock promotion campaigns deemed material by the issuer
- Changes to the company's shell status
- Other events the issuer considers to be of importance

⁴ "Integrated Newswire" shall mean a newswire service that is integrated with the OTC Disclosure & News Service and is included on OTC Markets Group's list of Integrated Newswires, as published on <https://www.otcm Markets.com/corporate-services/products/disclosure-and-news-service>

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

PHARMCHEM, INC.

2411 E. Loop 820 N., Fort Worth, TX 76118

855-458-4100

www.pharmchek.com

info@pharmchem.com

424990

Annual Report **For the Period Ending: 3/31/2022** **(the "Reporting Period")**

As of 3/31/2022, the number of shares outstanding of our Common Stock was:

5,103,273.

As of 12/31/2021, the number of shares outstanding of our Common Stock was:

5,103,273.

As of 12/31/2020, the number of shares outstanding of our Common Stock was:

5,852,593.

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control⁵ of the company has occurred over this reporting period:

Yes: ☐ No: ☒

⁵ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

N/A

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

DE-Active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

N/A

The address(es) of the issuer's principal executive office:

2411 E. Loop 820 N., Fort Worth, TX 76118

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

2) Security Information

Trading symbol:	<u>PCHM</u>
Exact title and class of securities outstanding:	<u>Common Stock</u>
CUSIP:	<u>717133102</u>
Par or stated value:	<u>\$0.001</u>

Total shares authorized:	<u>25,000,000</u>	as of date: <u>3/31/2022</u>
Total shares outstanding:	<u>5,103,273</u>	as of date: <u>3/31/2022</u>

Number of shares in the Public Float⁶: 2,097,353 as of date: 3/31/2022
Total number of shareholders of record: 400 as of date: 3/31/2022

All additional class(es) of publicly traded securities (if any):

Trading symbol: None
Exact title and class of securities outstanding: _____
CUSIP: _____
Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding: _____ as of date: _____

Transfer Agent

Name: Transfer Online
Phone: 502-227-2950
Email: info@transferonline.com
Address: 512 SE Salmon St., Portland, OR 97214

Is the Transfer Agent registered under the Exchange Act?⁷ Yes: ☒ No: ☐

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/2021</u> Common: <u>5,103,273</u> Preferred: <u>0</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per	Were the shares issued at a discount to market price at	Individual/ Entity Shares were issued to (entities must have individual with voting /	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.

⁶ "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

⁷ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

	returned to treasury)			share) at Issuance	the time of issuance? (Yes/No)	investment control disclosed).	Services Provided		
N/A									
Shares Outstanding on Date of This Report:									
Ending Balance:		Ending Balance							
Date 3/31/2022 Common: 5,103,273									
Preferred: 0									

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended June 30, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2019 through June 30, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

In September 2021, PharmChem, Inc. announced a Stock repurchase program to all common stock shareholders which will expire August 31, 2026. A total of 90,000 shares were repurchased and cancelled.

In October 2021, PharmChem authorized a \$3,000,000 Dutch Tender Offer to expired November 29, 2021. A total of 659,320 shares were purchased and cancelled.

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
N/A	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁸:

Name: Shana Veale
Title: VP/CFO
Relationship to Issuer: Employee

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
- D. Statement of Income;
- E. Statement of Cash Flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Attached

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

PharmChem, Inc. (the "Company" or "PharmChem") sells and distributes the PharmChek® Sweat Patch Device (the "Sweat Patch" or "PharmChek®"). PharmChek® is a system that uses sweat to detect the presence of illegal drugs. It consists of a transparent polyurethane outer covering, a small absorbent pad, and a release liner. A unique number is printed on the Sweat Patch for identification and anti-counterfeiting purposes. Unlike urinalysis, flushing or employing a diuretic to rid the body of drugs of abuse does not affect PharmChek® test results, since the drugs in the sweat

⁸ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

simply collect on the absorption pad until the pad is removed for analysis.

B. Please list any subsidiaries, parents, or affiliated companies.

None

C. Describe the issuers' principal products or services.

The Food and Drug Administration ("FDA") has cleared PharmChek® for detecting the use of cocaine, opiates (including heroin), amphetamines (including methamphetamine), phencyclidine, and marijuana. Once the Sweat Patch is removed from the donor, it is sent to a third-party, certified laboratory for screening and, if necessary, confirmation. The Company's customers include federal, state, and local governments, state and local drug courts, as well as independent companies which provide drug rehabilitation and other related services.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company's only property is a leased office in Fort Worth, TX -- the lease term ends in 2023.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Tice Brown</u>	<u>Director, Owner more than 5%</u>	<u>New York, NY</u>	<u>1,598,151</u>	<u>Common</u>	<u>31.3%</u>	<u> </u>
<u>Tim Eriksen</u>	<u>Director</u>	<u>Custer, WA</u>	<u>157,677</u>	<u>Common</u>	<u>3.1%</u>	<u> </u>
<u>Thompson Clark</u>	<u>Director</u>	<u>Raleigh, NC</u>	<u>0</u>	<u>Common</u>	<u>0%</u>	<u> </u>
<u>Tristam Jordan</u>	<u>Owner more than 5%</u>	<u>Ft. Lauderdale, FL</u>	<u>753,576</u>	<u>Common</u>	<u>14.8%</u>	<u> </u>
<u>Richard Jordan</u>	<u>Owner more than 5%</u>	<u>Ft. Lauderdale, FL</u>	<u>479,865</u>	<u>Common</u>	<u>9.4%</u>	<u> </u>
<u>Kerri Wagner</u>	<u>CEO/President</u>	<u>Volga, SD</u>	<u>100</u>	<u>Common</u>	<u><1%</u>	<u> </u>
<u>Shana Veale</u>	<u>VP/CFO</u>	<u>Fort Worth, TX</u>	<u>20</u>	<u>Common</u>	<u><1%</u>	<u> </u>

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

As to the owners of more than 5% shares above, the issuer is not aware of any such proceedings.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

As to the owners of more than 5% shares above, the issuer is not aware of any such proceedings.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

As to the owners of more than 5% shares above, the issuer is not aware of any such proceedings.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

As to the owners of more than 5% shares above, the issuer is not aware of any such proceedings.

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: William R. Rohrlich II, Shareholder
Firm: Winstead PC
Address 1: 600 Travis St., #5200
Address 2: Houston, TX 77002
Phone: 713-250-2634
Email: wrohrlich@winstead.com

Accountant or Auditor

Name: Joshua Agren
Firm: WhitleyPenn, LLP
Address 1: 640 Taylor St. #2200
Address 2: Fort Worth, TX 76102
Phone: 817-259-9270
Email: Joshua.agren@whitleypenn.com

Investor Relations

Name: None
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: None
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____

Email: _____

10) Issuer Certification


Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Kerri Wagner certify that:


1. I have reviewed this annual disclosure statement of PharmChem, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

4/22/22 _____ Date
 [CEO's Signature]
(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Shana Veale certify that:

1. I have reviewed this annual disclosure statement of PharmChem, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

4/22/22  _____ Date
[CFO's Signature]
(Digital Signatures should appear as "/s/ [OFFICER NAME]")